Through the analysis of infiltrating immune cells and chemokines, including type, number and location (tumor/stroma), they identified that the ratios of immune effectors to inhibitors are prognostic for the survival of patients, including the stroma CD3/FoxP3 ratio for lung adenocarcinoma [68], the tumor CD163/CD8 and CD163/CD20 ratios for mesothelioma [69], and the tumor CD10/CD20 ratio for lung squamous cell carcinoma [70]. This evidence concerns the gene CD8A and neoplasm.